Effects of a biologic agent in a patient with rheumatoid arthritis after …7thSpace Interactive (press release)The lymphoma went into complete remission after 6 courses of rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and predniso…
|
Bendamustine plus rituximab noninferior to standard therapy in NHL, mantle …
Healio In patients with slowly progressing non-Hodgkin’s lymphoma or mantle cell lymphoma, a regimen of bendamustine and rituximab is noninferior to standard treatment in terms of response rate and safety profile, according to findings from the BRIGHT study. |
|
Emerging Therapies in Development for Relapsed/Refractory CLL/SLL are …
PR Newswire (press release) It is expected that these agents will be added to rituximab-containing regimens, such as bendamustine (Teva Pharmaceutical Industries’ Treanda, Mundipharma’s Ribomustin/Levact, Symbio Pharmaceuticals/Eisai’s Treakisym) in combination with rituximab, … |
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid …MarketWatchPre-clinical studies show that BL-8040 is efficient, both alone and in combination with anti-cancer drugs such as Rituximab, Imatinib and Bortezomib in lymphoma, C…
BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid …Business Wire (press release)Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with anti-cancer drugs such as Rituximab, Imatinib and Bortezo…
Combination therapy with rituximab may benefit elderly patients with DLBCLHealioIn elderly patients with diffuse large B-cell lymphoma, a combination therapy regimen that includes rituximab appears to yield successful response rates, according to recen…
|
Lenalidomide plus rituximab induced durable responses in NHL
Healio The combination of lenalidomide and rituximab produced durable responses in a cohort of patients with relapsed/refractory or indolent non-Hodgkin’s lymphoma, according to results of a phase 2 study. Thirty patients received weekly rituximab (Rituxan, … |
|
Experimental drug could fight slow-growing cancers
OCRegister In one trial, 220 patients with recurrent chronic lymphocytic leukemia were given an intravenous drug called rituximab, a standard treatment. Half of participants were also given idelalisib twice a day in pill form. • Overall, 81 percent of patients … |
World Biosimilar Sector Developments Traced by FirstWord in New Report …Virtual-Strategy Magazine (press release)The leading amid the biosimilar and NCB development league is Rituximab (Rituxan/MabThera; Roche), possessing more than 30 individual pro…
World Biosimilar Sector Developments Traced by FirstWord in New Report …DigitalJournal.comThe leading amid the biosimilar and NCB development league is Rituximab (Rituxan/MabThera; Roche), possessing more than 30 individual programmes worldwide. The …